title: Serum levels of soluble syndecan-1 in Hodgkin's lymphoma.
abstract: BACKGROUND
  Syndecan-1 (CD138) is expressed by the Hodgkin-Reed-Sternberg (HRS) cells of classic Hodgkin's lymphoma (cHL), but not in nodular lymphocyte-predominant HL. Syndecan-1 may be involved in the interaction between HRS cells and the cellular and stromal microenvironment typical of nodular sclerosing HL.
  
  
  METHODS
  Serum levels of soluble syndecan-1 were determined by ELISA in 66 patients with HL and 14 age- and sex-matched healthy individuals.
  
  
  RESULTS
  The levels of syndecan-1 were higher in HL patients than controls (100.2 +/- 35.9 ng/ml vs. 67.9 +/- 24.5 ng/ml, p < 0.001). They marginally correlated with advanced age (p = 0.06), male gender (p = 0.07) and consequently high IPS (p = 0.01), but did not correlate with markers of tumor burden and prognosis, including serum interleukin-10 and soluble CD30. At 6 years, failure-free survival was 70 +/- 9% vs. 50 +/- 11% (p = 0.32) for patients with serum soluble syndecan-1 levels above or below the observed median value of 91 ng/ml.
  
  
  CONCLUSIONS
  The serum levels of syndecan-1 were elevated in patients with HL, but were not strongly correlated with other potential prognostic factors. Their effect on prognosis deserves further evaluation.
authors.affiliation: First Department of Internal Medicine and Department of Haematology, National and Kapodistrian University of Athens, Laikon University Hospital, Athens, Greece.
authors.forename: Theodoros P
authors.initials: TP
authors.lastname: Vassilakopoulos
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Kyrtsonis
authors.forename: Argiroula
authors.initials: A
authors.lastname: Papadogiannis
authors.forename: Gianpaolo
authors.initials: G
authors.lastname: Nadali
authors.forename: Maria K
authors.initials: MK
authors.lastname: Angelopoulou
authors.forename: Tatiana
authors.initials: T
authors.lastname: Tzenou
authors.forename: Maria N
authors.initials: MN
authors.lastname: Dimopoulou
authors.forename: Marina P
authors.initials: MP
authors.lastname: Siakantaris
authors.forename: Flora N
authors.initials: FN
authors.lastname: Kontopidou
authors.forename: Christina
authors.initials: C
authors.lastname: Kalpadakis
authors.forename: Styliani I
authors.initials: SI
authors.lastname: Kokoris
authors.forename: Evangelia M
authors.initials: EM
authors.lastname: Dimitriadou
authors.forename: Panayiotis
authors.initials: P
authors.lastname: Tsaftaridis
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pizzolo
authors.forename: Gerassimos A
authors.initials: GA
authors.lastname: Pangalis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000097:blood* / Q000473:pathology; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D011509:Proteoglycans / Q000097:blood*; D053668:Syndecan-1; D053667:Syndecans
chemical_list: D008562:Membrane Glycoproteins; D011509:Proteoglycans; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans